fda bpc-157 immunogenicity concerns Photos by Prof. Patrick J. Treacy (@ptreacy) · April 17, 2026 BPC-157 FDA Approval Status: Is
Description
Tingling in the hands
LH (mIU/mL) was increased compared to topical testosterone and placebo at 5.3 to 11.7, 3.9 to 1.4, and 3.9 to 3.7, respectively
MOT is for laboratory research use only
Research demonstrates that 5-amino-1MQ administration at 30 M concentration in adipocytes for 24 hours significantly increases intracellular NAD+ while reducing 1-MNA levels with an EC of 2.3 M
